ADC Therapeutics (ADCT) News Today

ADC Therapeutics (NYSE:ADCT) Stock Price Up 0.5%

ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 3,000,000 shares, a decrease of 6.0% from the July 15th total of 3,190,000 shares. Based on an average daily volume of 756,400 shares, the days-to-cover ratio is currently 4.0 days.

ADC Therapeutics SA (NYSE:ADCT - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for ADC Therapeutics in a research report issued to clients and investors on Wednesday, August 7th. Cantor Fitzgerald analyst E. Schmidt now anticipat

ADC Therapeutics (NYSE:ADCT - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. The firm had revenue of $17.41 million for the quarter, compared to the consensus estimate of $19.06 million. During the same period in the prior year, the company earned ($0.58) EPS.

Royal Bank of Canada restated an "outperform" rating and issued a $8.00 target price on shares of ADC Therapeutics in a report on Wednesday.

ADC Therapeutics (NYSE:ADCT) will be releasing earnings before the market opens on Tuesday, August 6, Zacks reports.

ADC Therapeutics SA (NYSE:ADCT - Get Free Report) major shareholder Redmile Group, Llc bought 400,000 shares of ADC Therapeutics stock in a transaction dated Monday, July 1st. The stock was purchased at an average price of $2.81 per share, with a total value of $1,124,000.00. Following the purchase, the insider now directly owns 12,995,040 shares in the company, valued at approximately $36,516,062.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

ADC Therapeutics SA (NYSE:ADCT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six brokerages that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the compa

ADC Therapeutics SA (NYSE:ADCT - Get Free Report) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 1,000,000 shares, an increase of 16.6% from the April 30th total of 857,600 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily volume of 566,800 shares, the days-to-cover ratio is currently 1.8 days.

ADC Therapeutics SA (NYSE:ADCT - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recom

Cantor Fitzgerald initiated coverage on ADC Therapeutics in a report on Thursday. They issued an "overweight" rating for the company.

ADC Therapeutics SA (NYSE:ADCT - Get Free Report) CEO Ameet Mallik sold 29,731 shares of the stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $4.48, for a total transaction of $133,194.88. Following the completion of the sale, the chief executive officer now owns 1,167,348 shares of the company's stock, valued at approximately $5,229,719.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

HC Wainwright dropped their price target on ADC Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday.

ADC Therapeutics (NYSE:ADCT - Get Free Report) released its earnings results on Monday. The company reported ($0.56) EPS for the quarter, meeting the consensus estimate of ($0.56). ADC Therapeutics had a negative net margin of 344.15% and a negative return on equity of 1,313.37%. During the same quarter in the previous year, the company posted ($0.74) earnings per share.

ADC Therapeutics (NYSE:ADCT) will be releasing earnings before the market opens on Monday, May 6, Zacks reports.

ADC Therapeutics SA (NYSE:ADCT - Free Report) - Investment analysts at HC Wainwright cut their Q1 2024 earnings per share estimates for shares of ADC Therapeutics in a research note issued on Monday, April 15th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.56) per sha

ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 993,100 shares, a growth of 5.7% from the March 15th total of 939,800 shares. Based on an average daily trading volume, of 791,000 shares, the short-interest ratio is presently 1.3 days. Currently, 1.8% of the shares of the company are short sold.